LLY

798.21

+0.15%↑

JNJ

152.19

-0.36%↓

ABBV

186.67

+0.02%↑

NVO

68.84

+1.16%↑

UNH

304.8

-0.09%↓

LLY

798.21

+0.15%↑

JNJ

152.19

-0.36%↓

ABBV

186.67

+0.02%↑

NVO

68.84

+1.16%↑

UNH

304.8

-0.09%↓

LLY

798.21

+0.15%↑

JNJ

152.19

-0.36%↓

ABBV

186.67

+0.02%↑

NVO

68.84

+1.16%↑

UNH

304.8

-0.09%↓

LLY

798.21

+0.15%↑

JNJ

152.19

-0.36%↓

ABBV

186.67

+0.02%↑

NVO

68.84

+1.16%↑

UNH

304.8

-0.09%↓

LLY

798.21

+0.15%↑

JNJ

152.19

-0.36%↓

ABBV

186.67

+0.02%↑

NVO

68.84

+1.16%↑

UNH

304.8

-0.09%↓

Search

Anavex Life Sciences Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

9.49 1.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.27

Max

9.72

Pagrindiniai rodikliai

By Trading Economics

Pajamos

915K

-11M

Pelnas, tenkantis vienai akcijai

-0.132

Darbuotojai

42

EBITDA

106K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+197.81% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

49M

776M

Ankstesnė atidarymo kaina

8.43

Ankstesnė uždarymo kaina

9.49

Naujienos nuotaikos

By Acuity

40%

60%

130 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Anavex Life Sciences Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-26 23:49; UTC

Uždarbis

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025-06-26 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025-06-26 21:30; UTC

Uždarbis

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Uždarbis

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025-06-26 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025-06-26 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025-06-26 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025-06-26 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025-06-26 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025-06-26 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025-06-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025-06-26 22:06; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:15; UTC

Uždarbis

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025-06-26 21:07; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025-06-26 21:06; UTC

Rinkos pokalbiai

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 20:52; UTC

Uždarbis

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025-06-26 20:51; UTC

Uždarbis

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025-06-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Anavex Life Sciences Corp Prognozė

Kainos tikslas

By TipRanks

197.81% į viršų

12 mėnesių prognozė

Vidutinis 28.5 USD  197.81%

Aukščiausias 42 USD

Žemiausias 15 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Anavex Life Sciences Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.275 / 9.312Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

130 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.